Sanofi's Kadmon confirms TGA approval of new treatment

“The Australian approval of RHOLISTIQ as part of the FDA’s Project Orbis initiative marks a key milestone in our effort to bring a new therapy to chronic GVHD patients in need across the globe,” said Haya Taitel, the chief commercial officer of Kadmon. …